home | help | email  

home
Contact
Research
Technology
Company
 

 

Neuromedics Technology Inc.

 

95 Pascal Lane

Austin, TX 78746

Tel.  (512) 633-2327

 

 

The Company

 

NeuroMedics Technology Inc.  has  been  established as a vehicle for the commercialization of EEG-driven light sound stimulation (EDLSS) technology as treatment for attention deficit/hyperactivity disorder.  .  NeuroMedics has acquired license to core technology patents and related intellectual property from NeuroTrain LLC and Synetic Systems Inc.,  and upon funding intends to complete a large  confirming clinical trial and thereafter to obtain FDA premarket approval (PMA) for the treatment of ADHD.  Please contact us for further details.

Management Team

Our management team concisely embodies  the skillset required to execute our business strategy.

Richard H. Sorenson, Chairman, President, and Chief Executive Officer

Richard Sorenson is the President and CEO of the Company and additionally serves on the board of directors of PointOne Telecommunications and Broadband Networks.  Mr. Sorenson was the President and CEO of PointOne Telecommunications Inc., a full-service voice and data communications company that he co-founded in 1998. In June 2000 Mr. Sorenson recruited a telecom veteran from Sprint Corporation to take over responsibilities as CEO.

A seasoned executive with 20 years in the high technology and medical industries, Mr. Sorenson is highly experienced in executive management, business development, mergers and acquisitions, corporate financial management and operations, and sales and marketing.  During his career prior to PointOne, he was with American Hospital Supply for 7 years and the Intermedics’ companies for 11 years.  Specifically, the operations he was involved with were heavily oriented towards pharmaceutical and bio-medical device research, development, manufacturing, and sales.

Recognizing the opportunity in the communications market, Mr. Sorenson was responsible for raising the necessary capital and building the management team to launch PointOne.  PointOne is a full service voice and data solutions company, offering converged services on a next-generation packet-based network.

Before founding PointOne, Mr. Sorenson enjoyed a successful career at Intermedics, Inc., where he began as Director of Finance. In that position, he contributed significantly to the turnaround of the financially troubled company, developing and implementing planning process to provide focus to operations. Later, he was a key member of the team responsible for the marketing and sale of Intermedics to Sulzer Limited of Switzerland, for $820 million.

Following the sale of Intermedics, Mr. Sorenson was named Vice President of Finance for Sulzer Carbomedics, Inc. and Sulzer Vascutek, Ltd., and later became Vice President for Business Development. While in that position, he was a member of the international team responsible for the $40 million acquisition of Vascutek, a Scottish vascular graft sales, marketing, and manufacturing organization.

Prior to his career at Intermedics, Mr. Sorenson held several positions of increasing responsibility at American Hospital Supply Corporation from 1981 through late 1987 when he was recruited to Intermedics, Inc.

A native of Hinsdale, Illinois, Mr. Sorenson earned a Bachelors of Science in Finance at the University of Colorado and a Masters in Management at Northwestern University in Evanston, IL. He has done additional coursework at Harvard University and is a CPA registered in the State of Illinois.

Mr. Sorenson is active in charitable and civic organizations, and. has served on the boards of the American Heart Association, Seton Hospital, Paramount Theater and has led significant fundraising efforts for those organizations, as well as the American Cancer Society, the Junior League, and various school and church activities.  Mr. Sorenson resides in Austin with his wife and two children.

 

Vice President, Clinical and Regulatory (Name Provided on Confidential Basis)

A Vice President for Clinical and Regulatory has been selected who will join the Company post-funding.  The individual’s information will be provided on a confidential basis in order to protect his current employment.

The individual has highly relevant medical device experience over a career of 20+ years in clinical and regulatory and has had extensive experience in developing appropriate systems to comply with the requirements of the United States Food and Drug Administration and with other regulatory agencies around the world. He also has extensive experience in supporting Marketing and Sales activities.

 

W. Daniel Vaughn

Vice President Administration, Director

Mr. Vaughn will join the Company in July 2002 upon departure from his current law firm, McLeod, Alexander, Powel, & Apffel, p.c.  Mr. Vaughn has served as legal counsel to the Company since its inception.  He is an officer/shareholder in the law firm of McLeod, Alexander, Powel & Apffel, P.C., and has been with the firm since 1977.  He has represented a variety of businesses, governmental and nonprofit entities, financial institutions and individual clients.

Mr. Vaughn earned his J.D. in 1975 from the University of Texas at Austin and a B.A. in Government from the University of Texas at Austin in 1972.  Mr. Vaughn is currently enrolled in the University of Houston Law Center LL.M. Program in Intellectual Property Law. 

 

Scientific Advisory Board

 

J.  F. Wernicke, Ph.D., M.D.

Doctor of Medicine, University of California, Irvine 1979

Ph.D. Biological Chemistry, University of California, Los Angeles 1974

B.S., Biochemistry, Texas A&M University, 1971

Dr. Wernicke has a highly relevant background and experience, creating an unusual fit as an advisor for the Company.  Dr. Wernicke’s experience covers pharmaceutical and medical device companies focused on neurological disorders, including ADHD, Depression, Parkinson’s disease, and Epilepsy.  Furthermore, with his specialty in neurology and fellowship at Washington University in Child Neurology, Dr. Wernicke is recognized as an expert in the areas specific to the Company.

Dr. Wernicke is employed with Eli Lilly & Company in the clinical development of atomoxetine for treatment of ADHD.  Dr. Wernicke has previously been instrumental in the clinical and regulatory development of fluoxetine (Prosac®) and pergolide (Permax®), both products approved by FDA.  Dr. Wernicke’s involvement has included the preparation and submission of NDA Supplements, direct negotiations with FDA, design and implementation of extensive safety analysis database, design and implementation of clinical development programs and individual clinical trials for numerous compounds, and support of international clinical trials and regulatory activities.

While at Cyberonics, Dr. Wernicke was instrumental in the preparation and submission of PMA for NeuroCybernetic Prosthesis (NCP®) [implantable vagus nerve stimulator for treatment of refractory epilepsy], design and implementation of multinational clinical trials for devices using scientific approaches common to drug trials, direct negotiations with FDA regarding submissions and approval process, statistical analysis using SAS, and the management of clinical and regulatory affairs group.

Dr. Wernicke is credited with 8 issued patents.  Dr. Wernicke has published extensively in the areas of neurological and psychiatric disorders.

 

Harold L. Russell, Ph.D.
Ph.D., University of Houston, 1966, Clinical Psychology.

Dr. Russell is a semi-retired clinical psychologist with a private practice in Galveston, Texas. Dr. Russell is an adjunct research professor in the Department of Gerontology and Health Promotion at The University of Texas Medical Branch at Galveston.  Prior to leaving full time work at UTMB to enter private practice in 1979, Dr. Russell was an instructor and assistant professor.  Dr. Russell has had significant interest throughout his professional career in psycho-neurological problems that are considered difficult to treat.  Dr. Russell has been extensively involved in research and has published.  Much of Dr. Russell's published research has been in collaboration with Dr. Carter over a number of years, including the groundbreaking research involving EDLSS technology.

 

Ben G. Raimer, M.D.

Vice President for Community Outreach, UTMB

M.D. University of Texas Medical Branch School of Medicine, 1974

Pediatric Residency Program at UTMB’s Hospitals in 1977

MA, University of Texas Medical Branch, 1970, Human Genetics

BS, East Texas Baptist College, 1969

American Board of Pediatrics Certified and is a Fellow of the American Academy of Pediatrics

Dr. Raimer served as a community-based pediatrician in Galveston County from 1977 until 1993, when he joined UTMB as medical director for the Primary Care Outpatient Clinics. He has served on the staff at Texas City Mainland Hospital, as chief of staff at St Mary’s Hospital in Galveston, and as president of the Galveston County Medical Society. In 1997, he became the chief physician executive for UT-MED. Dr. Raimer continues to provide medical care for children with learning and development disorders and serves as professor of pediatrics and family medicine.

Dr. Raimer was appointed by Governor William P. Clements to the Children’s Trust Fund of Texas and served an eight-year term with the council. In 1997, Governor George W. Bush appointed him chair of the Texas Statewide Health Coordinating Council, which is charged with producing the State Health Plan. Dr. Raimer was later appointed by Governor Bush to chair the Texas Correctional Managed Health Care Committee.

In recognition of his work to prevent child abuse, Raimer received the 1998 Ray Helfer Award on behalf of the National Alliance of Children’s Trust and Prevention Funds and the American Academy of Pediatrics Section on Child Abuse. He also received UTMB’s Nicholas and Katherine Leone Award for Administrative Excellence in 1998.

 

Advisors

John L. Carter, Ph.D.
Ph.D., University of Texas at Austin, 1966, Educational Psychology and Special Education.

Dr. Carter is a retired educational psychologist and professor of education.   During his thirty years at the University of Houston, Dr. Carter received over 25 federal grants and chaired 12 doctoral dissertations in his areas of specialty.  Dr. Carter received national recognition for some of his early studies on the long lasting (ten year) effects of early educational interventions. His findings were used as part of the support for the establishment of the Head Start program.  Dr. Carter has conducted and participated in extensive research in the areas of brain function and learning disabilities.  Much of Dr. Carter's research has involved the long-term effects of light and sound stimulation.  Among the groundbreaking research projects in which Dr. Carter was involved were the studies of EDLSS technology in treating ADHD children funded by Phase I and II Small Business Innovation Research grants through the U. S. Department of Education. Dr. Carter has published extensively and conducted many presentations prior to his retirement.

 

Robert Austin
President, Synetic Systems Inc.

Mr. Austin obtained his A.S. in Chemical Technology (SCCC, 1976) and continued his studies at the University of Washington (1977-81).  During the 1980's he developed several microprocessor based computer music projects, and in 1987 began developing the light and sound stimulation system he brought to market in 1988, when he founded Synetic Systems Inc.  During subsequent years he has designed or overseen the design of numerous light and sound stimulation systems, including three that utilized EEG measurements.

 

SYNERGOS, Inc.

Consultants in Biomedical Research

SYNERGOS, Inc. is a Contract Research Organization that provides comprehensive clinical research and development services, from study design through regulatory submission.  SYNERGOS has substantial experience in pharmaceuticals, medical devices, and biotechnology product development, with significant expertise in numerous therapeutic and diagnostic areas.  To date, SYNERGOS has managed, analyzed, and produced reports for each type of regulatory submission required by the FDA, including multiple NDAs and PMAs.  In particular, SYNERGOS has been involved in highly relevant clinical and regulatory work for Medtronic’s Neurological division and Cyberonics, Inc, Vagus Nerve Stimulation system.  SYNERGOS has provided strategic regulatory and clinical direction to the Company and, post funding, the Company intends to engage SYNERGOS to manage much of the clinical and regulatory aspects of the clinical trials and regulatory submissions.

 

Copyright 2002 Neuromedics Technology Inc. 

  home ] Contact ] Research ] Technology ] [ Company ]